Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial

BACKGROUND: The reporting of adverse drug reactions (ADR) by patients represents an interesting challenge in the field of pharmacovigilance, but the reporting system is not adequately implemented in France. In 2015, only 20 MS patients in France reported ADR due to first-line disease-modifying drugs...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Trials
Autores principales: Defer, Gilles, Le Caignec, Florian, Fedrizzi, Sophie, Montastruc, François, Chevanne, Damien, Parienti, Jean-Jacques, Peyro-Saint-Paul, Laure
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845183/
https://ncbi.nlm.nih.gov/pubmed/29523169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-018-2560-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares